Table 4.
Overview of the extracted outcome parameters.
| Reference | Year | Number of Patients with pmGC and CRS + HIPEC | Median PCI | Median OS | Clavien–Dindo ≥III° |
Anastomotic Leakage Rate |
|---|---|---|---|---|---|---|
| Fujimoto et al. [29] | 1988 | 9 | ns | ns | ns | ns |
| Fujimoto et al. [30] | 1997 | 30 | ns | ns | ns | ns |
| Chen et al. [31] | 1997 | 6 | ns | ns | ns | ns |
| Sayag-Beaujard et al. [32] | 1999 | 18 | ns | ns | ns | ns |
| Loggie et al. [33] | 2000 | 22 | ns | ns | ns | ns |
| Glehen et al. [34] | 2004 | 21 | ns | 10.3 months 1-year: 48.1% 2-year: 19.0% 5-year: 16.0% |
13 (27%) | 0/49 (0%) |
| Yonemura et al. [35] | 2005 | 42 | ns | 11.5 months 5-year: 6.7% |
ns | 7/107 (6.5%) |
| Kusamura et al. [36] | 2006 | 12 | ns | ns | ns | ns |
| Roviello et al. [37] | 2006 | 6 | ns | ns | ns | ns |
| Scaringi et al. [38] | 2008 | 26 | ns | 15 months | ns | ns |
| Yang et al. [39] | 2009 | 12 | ns | ns | ns | ns |
| Piso et al. [40] | 2009 | 11 | ns | ns | ns | 0/15 (0%) |
| Yang et al. [41] | 2010 | 28 | 12 | 1-year: 50.0% 2-year: 42.8% |
ns | ns |
| Li et al. [42] | 2010 | 10 | ns | 11.8 months 1-year: 52.5% 3-year: 13.2% 5-year: 5.5% |
ns | 0/10 (0%) |
| Glehen et al. [43] | 2010 | 147 | 9.4 (±7.7) | 9.2 months 1-year: 43% 3-year: 18% 5-year: 13% |
34.30% | ns |
| Yang et al. [44] | 2011 | 34 | 15 | 11 months 1-year: 41.2% 2-year: 14.7% 3-year: 5.9% |
ns | 0/35 (0%) |
| Cotte et al. [45] | 2011 | 12 | ns | ns | ns | 0/12 (0%) |
| Mizumoto et al. [46] | 2012 | 16 | 10 (±10) * | ns | 38% | ns |
| Wu et al. [47] | 2013 | 32 | ns | 15.5 months | ns | ns |
| Yarema et al. [48] | 2014 | 20 | 3.40 | 12 ± 1.6 months | ns | 1 (2%) |
| Tabrizian et al. [49] | 2014 | 12 | ns | 3-year: 16.6% | ns | ns |
| Rudloff et al. [50] | 2014 | 9 | ns | 11.3 months | 8 (89%) | 2 (22%) |
| Magge et al. [51] | 2014 | 23 | 10.5 | 9.5 months 1-year: 49.6% 3-year: 17.9% |
52% | 3 (13%) |
| Levine et al. [52] | 2014 | 46 | ns | 6.1 months | see Ref [53] | ns |
| Kim et al. [53] | 2014 | 9 | ns | 16 months | ns | ns |
| Königsrainer et al. [54] | 2014 | 13 | ns | 8.9 months | 11 (Grade 1–5) | 0 (0%) |
| Graziosi et al. [55] | 2014 | 15 | ns | ns | 4 (11.1%) | 0 (0%) |
| Polanco et al. [56] | 2015 | 24 | 13 | ns | see Ref [57] | ns |
| Desantis [57] | 2015 | 14 | ns | ns | ns | ns |
| Wu [58] | 2016 | 50 | 15 | 24.8 months | 12 (23.1%) | 1 (1%) |
| Kopanakis [59] | 2017 | 14 | 15 | ns | ns | ns |
| Rihuete Caro [60] | 2018 | 32 | ns | ns | 38% | ns |
| Montori et al. [61] | 2018 | 26 | 8 | 16 months 1-year: 70.8% 3-year: 21.3% |
9 (25.7%) | ns |
| Yarema [62] | 2019 | 70 | ns | PCI 0–6: 15 months PCI > 6: 8.2 months |
ns | 7 (6.5%) |
| Solomon [63] | 2019 | 18 | ns | 12 months | see Ref [63] | ns |
| Rau [4] | 2019 | 58 | 8.3 (±5.7) * | 9.8 months | 14 (62%) | ns |
| Manzanedo [64] | 2019 | 84 | 6 | 21.2 months 1-year: 79.9% 3-year: 30.9% |
30 (34.4%) | ns |
| Kimbrough [65] | 2019 | 28 | 12 | 10 months | 5 (18%) | 2 (7%) |
| Hotopp [66] | 2019 | 26 | 10 | 17 months | ns | 2 (7.7%) |
| Bonnot [17] | 2019 | 180 | 6 | 18.6 months | 53.70% | ns |
| Braeuer [67] | 2020 | 37 | 3.75 ±1.9 * | 33.8 months | 3 (37.5%) | ns |
| Koemans [68] | 2021 | 23 | 2 | 15 months | ns | ns |
* Mean (± standard deviation); OS: overall survival; ns: not stated.